BlackRock, Inc. Reduces Stake in Fulcrum Therapeutics Inc.

BlackRock, Inc. has filed a Schedule 13G/A amendment indicating a reduction in its ownership stake in Fulcrum Therapeutics Inc. As of September 30, 2025, BlackRock owns 3,270,322 shares, representing 6.0% of the common stock. This marks a decrease of 2,660,019 shares, or 44.85%, from its previous holdings. The filing also notes that various persons have the right to receive dividends or direct the sale of these shares, but no single person's interest exceeds 5% of the total outstanding shares. The filing was signed by Spencer Fleming, Managing Director, on October 17, 2025.